Cogent Biosciences Announces Participation in the Jefferies Global Healthcare Conference
Cogent Biosciences (NASDAQ: COGT), a biotechnology company specializing in precision therapies for genetically defined diseases, has announced its upcoming presentation at the Jefferies Global Healthcare Conference on June 5, 2025, at 7:35 a.m. ET. The presentation will be accessible via webcast on the company's investor relations website, with a replay available for 30 days.
Additionally, the company disclosed the approval of inducement equity awards for five new employees under its 2020 Inducement Plan. The awards consist of options to purchase 127,000 shares of Cogent common stock, featuring a 10-year term and a four-year vesting schedule.
Cogent Biosciences (NASDAQ: COGT), un'azienda biotecnologica specializzata in terapie di precisione per malattie geneticamente definite, ha annunciato la sua prossima presentazione alla Jefferies Global Healthcare Conference il 5 giugno 2025, alle 7:35 ET. La presentazione sarà disponibile in webcast sul sito dedicato agli investitori dell'azienda, con una replica fruibile per 30 giorni.
Inoltre, la società ha comunicato l'approvazione di premi azionari di incentivo per cinque nuovi dipendenti nell'ambito del suo Piano di Incentivo 2020. I premi consistono in opzioni per l'acquisto di 127.000 azioni ordinarie di Cogent, con una durata di 10 anni e un piano di maturazione quadriennale.
Cogent Biosciences (NASDAQ: COGT), una empresa biotecnológica especializada en terapias de precisión para enfermedades genéticamente definidas, ha anunciado su próxima presentación en la Jefferies Global Healthcare Conference el 5 de junio de 2025 a las 7:35 a.m. ET. La presentación estará disponible vía webcast en el sitio web de relaciones con inversores de la compañía, con una repetición accesible durante 30 días.
Además, la empresa ha dado a conocer la aprobación de premios de acciones de incentivo para cinco nuevos empleados bajo su Plan de Incentivos 2020. Los premios consisten en opciones para comprar 127,000 acciones comunes de Cogent, con un plazo de 10 años y un calendario de adquisición de derechos de cuatro años.
코전트 바이오사이언스(NASDAQ: COGT)는 유전적으로 정의된 질환을 위한 정밀 치료법에 특화된 생명공학 회사로, 2025년 6월 5일 오전 7시 35분(동부시간)에 제퍼리스 글로벌 헬스케어 컨퍼런스에서 발표할 예정임을 발표했습니다. 발표는 회사 투자자 관계 웹사이트를 통해 웹캐스트로 제공되며, 30일간 다시보기 서비스를 이용할 수 있습니다.
또한, 회사는 2020년 인덕스먼트 플랜에 따라 다섯 명의 신규 직원에게 인센티브 주식 보상을 승인했다고 밝혔습니다. 보상은 10년 만기와 4년 베스팅 일정이 적용된 코전트 보통주 127,000주 매수 옵션으로 구성됩니다.
Cogent Biosciences (NASDAQ : COGT), une entreprise de biotechnologie spécialisée dans les thérapies de précision pour les maladies génétiquement définies, a annoncé sa prochaine présentation à la Jefferies Global Healthcare Conference le 5 juin 2025 à 7h35 ET. La présentation sera accessible en webcast sur le site des relations investisseurs de la société, avec une rediffusion disponible pendant 30 jours.
Par ailleurs, la société a annoncé l'approbation d'attributions d'actions incitatives pour cinq nouveaux employés dans le cadre de son Plan d'Incitation 2020. Ces attributions comprennent des options d'achat de 127 000 actions ordinaires Cogent, avec une durée de 10 ans et un calendrier d'acquisition des droits sur quatre ans.
Cogent Biosciences (NASDAQ: COGT), ein Biotechnologieunternehmen, das sich auf Präzisionstherapien für genetisch definierte Krankheiten spezialisiert hat, hat seine bevorstehende Präsentation auf der Jefferies Global Healthcare Conference am 5. Juni 2025 um 7:35 Uhr ET angekündigt. Die Präsentation wird per Webcast auf der Investor-Relations-Website des Unternehmens zugänglich sein, mit einer Wiederholung, die für 30 Tage verfügbar ist.
Zusätzlich gab das Unternehmen die Genehmigung von Anreizaktien für fünf neue Mitarbeiter im Rahmen seines Inducement-Plans von 2020 bekannt. Die Auszeichnungen bestehen aus Optionen zum Kauf von 127.000 Cogent-Stammaktien mit einer Laufzeit von 10 Jahren und einem vierjährigen Vesting-Zeitplan.
- None.
- None.
WALTHAM, Mass. and BOULDER, Colo., May 29, 2025 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced its presentation at the Jefferies Global Healthcare Conference on Thursday, June 5, 2025 at 7:35 a.m. ET.
A live webcast will be available on the Investors & Media page of Cogent’s website at investors.cogentbio.com. A replay of the webcast will be available approximately two hours after the completion of the event and will be archived for up to 30 days.
Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Cogent also announced today that, on May 19, 2025, the Compensation Committee of Cogent’s Board of Directors, made up entirely of independent directors, approved the grants of “inducement” equity awards to five new employees under the company’s 2020 Inducement Plan with a grant date of May 27, 2025. The awards were approved in accordance with Listing Rule 5635(c)(4) of the corporate governance rules of the Nasdaq Stock Market. The employees received, in the aggregate, nonqualified options to purchase 127,000 shares of Cogent common stock. Each option has a 10-year term, an exercise price equal to the closing price of Cogent’s common stock on the grant date, and a four-year vesting schedule with
About Cogent Biosciences, Inc.
Cogent Biosciences is a biotechnology company focused on developing precision therapies for genetically defined diseases. The most advanced clinical program, bezuclastinib, is a selective tyrosine kinase inhibitor that is designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. KIT D816V is responsible for driving systemic mastocytosis, a serious disease caused by unchecked proliferation of mast cells. Exon 17 mutations are also found in patients with advanced gastrointestinal stromal tumors (GIST), a type of cancer with strong dependence on oncogenic KIT signaling. The company also has an ongoing Phase 1 study of its novel internally discovered FGFR2 inhibitor. In addition, the Cogent Research Team is developing a portfolio of novel targeted therapies to help patients fighting serious, genetically driven diseases targeting mutations in ErbB2, PI3Kα and KRAS. Cogent Biosciences is based in Waltham, MA and Boulder, CO. Visit our website for more information at www.cogentbio.com. Follow Cogent Biosciences on social media: X (formerly known as Twitter) and LinkedIn. Information that may be important to investors will be routinely posted on our website and X.
Contact:
Christi Waarich
Senior Director, Investor Relations
christi.waarich@cogentbio.com
617-830-1653
FAQ
When is Cogent Biosciences (COGT) presenting at the Jefferies Global Healthcare Conference 2025?
What inducement grants did Cogent Biosciences (COGT) approve in May 2025?
Where can investors watch Cogent Biosciences' (COGT) Jefferies conference presentation?
What is Cogent Biosciences' (COGT) main business focus?
